Hemophilia A
Background: Hemophilia is a group
of bleeding disorders resulting from coagulation factor VIII(A), IX(B), or
XI(C) deficiency. The bleeding tendancy is different from severe to mild
depending on the levels of deficiency. Replacement therapy with exogenous factor
or plasma can effectively ameliorate the bleeding complications in hemophilia patients.
Model: Anti-FVIII antibody or
specific antisense induced hemophilia
Standard
study duration: 4-8 weeks
Clinical endpoint: Bleeding tests,
coagulation tests, factor assays…
Features: Hemostasis, hematology, coagulation factors, potency, tolerability, and safety assessment…
For more information about these models, please contact Mr. James Song, mailto:james.song@prisysbiotech.com